Lymphoma

Research

UCSF Medical Center is one of the world's leading institutions in biomedical and health science research. We are part of the University of California San Francisco, which has more than 3,000 ongoing research projects to help patients live longer, healthier lives. In the past 10 years, three UCSF faculty have won Nobel prizes for work leading to new strategies for detection and treatment of cancer and for the discovery of prions, a new infectious agent implicated in rare, slowly progressing brain diseases such as mad cow disease.

Our patients and the physicians who refer their patients to UCSF Medical Center look to us for opportunities to benefit from our research involving patients, which are clinical trials. Clinical trials make new medications, treatments and surgical procedures available to our patients before they're widely available to the general public.

Clinical Protocols for Hematology and Bone Marrow Transplant

Hodgkin's Disease

• A Phase I/II study of the drug, Gemcitabine (Gemzar®/Vinorelbine (Navelbine®)/ Liposomal Doxorubicin (Doxil®) in patients with relapsed or refractory Hodgkin's disease. (CALGB 59804)

• A randomized phase III study of the treatments, ABVD versus Stanford V + radiation therapy in patients with locally extensive and advanced stage Hodgkin's disease with 0 to 2 risk factors. (CALGB 59905)

Non-Hodgkin's Lymphoma

• A phase II study of 506U78 (NSC #686673, IND #52611) in patients with cutaneous T-cell lymphoma (CTCL) or with refractory or relapsed non-cutaneous peripheral T-cell lymphoma (PTCL). (CALGB 59901)

• A phase II study of intensive induction chemotherapy followed by autologous stem cell transplantation plus immunotherapy for patients with mantle cell lymphoma. (CALGB 59909)

• A phase II study of dose-adjusted EPOCH-Rituximab chemotherapy for patients with previously untreated aggressive CD20+ B-cell Non-Hodgkin's lymphoma. (CALGB 50103)

• A randomized phase II trial of the treatment, EPOCH either taken concurrently or sequentially with the drug, Rituximab in patients with intermediate or high-grade HIV-associated B-cell Non-Hodgkin's lymphoma. (AMC 034)

• Pilot study investigating the safety and feasibility of autologous peripheral blood stem cell transplantation in patients with relapsed AIDS-related lymphoma. (AMC 020)

• Phase II trial of the drugs, Rituximab plus FavId (Tumor Specific Idiotype KLH) and GM-CSF immunotherapy in patients with grade 1 or 2 follicular B-cell lymphoma. (CC# 02304)

• An open label, dose-finding phase I study evaluating the safety, tolerability and action of SL-11047 in patients with refractory lymphoma. (CC# 02303)

• A phase I/II study of Rituximab plus Vincristine Sulfate Liposomes injection for the treatment of relapsed or refractory aggressive Non-Hodgkin's lymphoma. (CC# 01301)

• An open label phase I study evaluating the safety, tolerability and action of SL-11047 in AIDS patients with Non-Hodgkin's lymphoma. (CC# 01351)

More information about clinical trials for lymphoma can be found in clinicaltrials.gov or on the UCSF Helen Diller Family Comprehensive Cancer Center Web site.

Reviewed by health care specialists at UCSF Medical Center.
Last updated November 15, 2007